Lupus Nephritis in Men: A Series of 25 Cases
Archives of Men's Health,
Vol. 8 No. 1 (2024),
31 July 2024
,
Page e13
https://doi.org/10.22037/amh.v8i1.48947
Abstract
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease more common in women than in men. This study analyzes the clinical, biological, immunological, and evolutionary features of lupus nephritis in men. Methods: This study involved 25 male patients diagnosed with lupus nephritis between 2020 and 2024, selected from 90 lupus patients. All met the ACR or SLICC criteria and had kidney damage. Results: The average age at diagnosis was 34.2 years (range: 16–51). Six patients were hypertensive, none were diabetic. Renal failure was observed in 15 patients, hematuria in 12, nephrotic syndrome in 15, and non-nephrotic proteinuria in 8. Most patients had lupus membranoproliferative glomerulonephritis (Class IV, 19 patients), followed by extra-membranous glomerulonephritis (Class V, 4 patients). Extra-renal involvement included hematological disorders (18 patients) and joint issues (16 patients), with two patients having antiphospholipid syndrome. For treatment, 21 patients received intravenous methylprednisolone and cyclophosphamide, while 4 received oral mycophenolate mofetil (MMF). Maintenance therapy was with MMF (4 patients) or azathioprine (15 patients). After two years, 8 patients achieved complete remission, 2 had partial remission, 5 relapsed, and 4 progressed to chronic kidney disease, including 2 with end-stage renal disease. Conclusion: Lupus nephritis generally has a favorable course, although relapses and chronic kidney disease are observed. Personalized management is crucial for improving long-term outcomes.
- Lupus nephritis
- renal failure
- immunosuppression
- chronic kidney disease
How to Cite
References
Benhmida M, Chaabouni Y, Kammoun K, Yaich S, Kharrat M, Jarraya F, et al. Néphropathie lupique chez l’homme. À propos de 20 cas. Néphrologie Thérapeutique. 2011 Sep 1;7(5):377–8.
Cheikh S, Kharrat A, Soldi C, Khayat SS, Mtioui N, Medkouri G, et al. La néphropathie lupique : quelle particularité chez l’homme ? Rev Médecine Interne. 2023 Jun 1;44:A254.
Barhoumi H, Chaabouni Y, Hchicha J, Kammoun K, Kharrat. M. Néphropathie lupique chez l’homme : à propos de 24 cas. 2017.
Wang H, Ren Y le, Chang J, Gu L, Sun LY. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Arch Rheumatol. 2018 Mar;33(1):17–25.
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019 Oct 1;78(10):1296–304.
Ebana HDFM, Mahamat M, Lekpa FK, Jemmy CK, Ashuntantang G, Halle MP. [Clinical profile and survival of patients with lupus nephritis in the department of nephrology in Cameroon: a single-center study]. Pan Afr Med J. 2022;41:205.
Brijlal U, Bates WD, Moosa MR. Lupus nephritis in the Western Cape, a high prevalence area: an experience over three decades. Lupus. 2017 Oct 1;26(11):1228–34.
Williams JN, Drenkard C, Lim SS. The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus. Rheumatol Oxf Engl. 2023 Mar 29;62(Suppl 1):i10–4.
Buie J, McMillan E, Kirby J, Cardenas LA, Eftekhari S, Feldman CH, et al. Disparities in Lupus and the Role of Social Determinants of Health: Current State of Knowledge and Directions for Future Research. ACR Open Rheumatol. 2023 Aug 2;5(9):454–64.
Izidbih Y, Snoussi M, Damak C, Frikha F, Marzouk S, Kammoun K, et al. Particularités du lupus érythémateux systémique masculin. Néphrologie Thérapeutique. 2022 Jan 23;16:288–320.
David C, Arango-Franco CA, Badonyi M, Fouchet J, Rice GI, Didry-Barca B, et al. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus. J Exp Med. 2024 Aug 5;221(8):e20232066.
Petri M. Pregnancy and Systemic Lupus Erythematosus. Best Pract Res Clin Obstet Gynaecol. 2020 Apr 1;64:24–30.
Cervera R, Doria A, Amoura Z, Khamashta M, Schneider M, Guillemin F, et al. Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev. 2014 Jun 1;13(6):621–9.
Arnaud L. Épidémiologie du lupus systémique : des approches traditionnelles aux méga-données. Bull Académie Natl Médecine. 2022 Jan 1;206(1):17–22.
Andrade RM, Alarcón GS, Fernández M, Apte M, Vilá LM, Reveille JD. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007;56(2):622–30.
Duarte-García A, Hocaoglu M, Valenzuela-Almada M, Osei-Onomah SA, Dabit JY, Sanchez-Rodriguez A, et al. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Ann Rheum Dis. 2022 Sep 1;81(9):1260–6.
Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol Hoboken NJ. 2021 Jun;73(6):991–6.
Perge B, Papp G, Bói B, Markóth C, Bidiga L, Farmasi N, et al. Prognostic Factors of the Progression of Chronic Kidney Disease and the Development of End-Stage Renal Disease in Patients with Lupus Nephritis: A Retrospective Cohort Study. J Clin Med. 2025 Jan;14(3):665.
Pons-Estel G, Aspey L, Bao G, Pons-Estel B, Wojdyla D, Saurit V, et al. Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus. 2016 May 26;26:73–83.
Fava A, Fenaroli P, Rosenberg A, Bagnasco S, Li J, Monroy-Trujillo J, et al. History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis. Rheumatol Oxf Engl. 2021 Oct 19;61(6):2483–93.
Bashal F. Hematological Disorders in Patients with Systemic Lupus Erythematosus.
Velo-García A, Castro SG, Isenberg DA. The diagnosis and management of the haematologic manifestations of lupus. J Autoimmun. 2016 Nov;74:139–60.
Bortoluzzi A, Scirè CA, Govoni M. Attribution of Neuropsychiatric Manifestations to Systemic Lupus Erythematosus. Front Med. 2018;5:68.
Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010 Feb;39(4):257–68.
Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021 Sep;17(9):515–32.
Parodis I, Lindblom J, Barturen G, Ortega-Castro R, Cervera R, Pers JO, et al. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort. Ann Rheum Dis. 2024 Jul 1;83(7):889–900.
Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022 Oct;132:102871.
Banos A, Bertsias G. Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention. Curr Rheumatol Rep. 2023;25(10):183–91.
Rojas-Rivera JE, García-Carro C, Ávila AI, Espino M, Espinosa M, Fernández-Juárez G, et al. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Clin Kidney J. 2023 Mar 22;16(9):1384–402.
Sachdeva R, Pal R. The influence of reproductive hormones on systemic lupus erythematosus. Explor Immunol. 2022 Jun 7;2(3):351–62.
Langefeld CD, Ainsworth HC, Cunninghame Graham DS, Kelly JA, Comeau ME, Marion MC, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017 Jul 17;8:16021.
Kavrul Kayaalp G, Casares-Marfil D, Şahin S, Kasapçopur Ö, Sözeri B, Aktay Ayaz N, et al. Rare Turner syndrome and lupus coexistence with insights from DNA methylation patterns. Clin Immunol. 2024 Sep 1;266:110310.
Laurynenka V, Harley JB. The 330 risk loci known for systemic lupus erythematosus (SLE): a review. Front Lupus 2024
- Abstract Viewed: 166 times
- pdf Downloaded: 114 times